Institute for Cancer Research
Institute for Cancer Research has since its foundation in 1954 played a central role within the field of cancer research both in Norway and internationally. The Institute has seven research departments and more than 320 employees, master students included. About 70% of the employees and projects are externally funded.
The Institute has internationally strong research groups within biochemistry, cell and tumor biology, genetics, radiation biology, immunology and cancer prevention. For more than 30 years there has been a close interaction between researchers at the Institute and cancer surgeons, oncologists and pathologists. This emphasis on translational science has resulted in numerous clinical protocols based on in-house research, and the Institute is a key partner in the Comprehensive Cancer Center, organizationally under the Division of Surgery and Cancer Treatment at Oslo University Hospital.
Acting Inst. Head
Scientific production - Institute for Cancer Research
Annual report 2015 (pdf format)
The Institute is engaged in both basic and translational cancer research involving experimental research on model organisms from various evolutionary levels as well as human material from all types of cells and tissues. The co-localisation with a large cancer hospital fulfils the premises for advanced medical research across sciences, a necessity towards the goals of individualised diagnostics and treatment for cancer patients.
Jørgen Wesche appointed group leader for the Mesenchymal Cancer Biology Group at the Department of Tumor Biology
Mar 15, 2017
Prestigious research prize from the Norwegian Cancer Society to pioneer in autophagy research
Mar 7, 2017
Mar 6, 2017
Mar 2, 2017
Inst. for Cancer Research
Evaluation of Prognostic and Predictive Significance of Circulating MicroRNAs in Ovarian Cancer Patients
Dis Markers, 2017, 3098542
New Molecular Assay for the Proliferation Signature in Mantle Cell Lymphoma Applicable to Formalin-Fixed Paraffin-Embedded Biopsies
J Clin Oncol, JCO2016707901 (in press)
Journal Impact Factor > 5, first or last author from the Institute for Cancer Research
The diverse roles of glutathione-associated cell resistance against hypericin photodynamic therapy
Redox Biol, 12, 191-197 (in press)
TORC1 Inhibits GSK3-Mediated Elo2 Phosphorylation to Regulate Very Long Chain Fatty Acid Synthesis and Autophagy
Cell Rep, 18 (8), 2073-2074